“Then recently, of course, with the single-port device, that has truly allowed us to be less invasive with our robotic approaches,” says Adam Lorentz, MD, FACS. In this video, Adam Lorentz, MD, FACS, ...

As this is a balloon, the question has come up on whether it would be appropriate to report Current Procedural Terminology (CPT) code 55874 (Transperineal placement of biodegradable material, ...

Fast track designation for 64Cu-SAR-bisPSMA enables accelerated development and review for prostate cancer imaging. Phase 1/2 COBRA trial showed 64Cu-SAR-bisPSMA's efficacy in detecting lesions missed ...

This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context ...

"I know this year we're going to see even more companies producing more products, more results, and hopefully really help change and improve patient outcomes, especially when it comes to overactive ...

“They come out of the fellowship competent and competitive in the field to any urology position that they're interested in,” says Tania Solomon, PA-C, MSc. In this video, Tania Solomon, PA-C, MSc, ...

Patient-centered pathology reports (PCPRs) significantly improve patient comprehension of prostate cancer diagnosis and risk levels compared to standard reports. In the study, 93% of PCPR recipients ...

"If you can do this surgery well, patients actually go back to living a normal life, and they're immensely, immensely happy," says Jaspreet S. Sandhu, MD. In this video, Jaspreet S. Sandhu, MD, ...

UGN-101 showed a 68% three-year RFS rate in low-grade UTUC patients, with a median follow-up of 23.5 months. Maintenance therapy significantly improved RFS, but further studies are needed to confirm ...

A recent systematic review published in Annals of Internal Medicine showed inconsistent findings between observational and randomized studies on the impact of tissue-based genomic classifier tests on ...

"The approach is often to identify what treatments the patients have tried already, so we don't try those again, and then have a discussion about the pros and cons," says J. Quentin Clemens, MD, MSCI.

Annual cost analyses suggest that some newer therapies may have higher up-front costs but can be more economical in the long run due to fewer recurrences and less frequent administration. How does the ...